Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of Various Formulations of PWT-143 in Healthy Subjects

Trial Profile

Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of Various Formulations of PWT-143 in Healthy Subjects

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs ME 401 (Primary)
  • Indications Haematological malignancies
  • Focus Adverse reactions; First in man
  • Sponsors MEI Pharma
  • Most Recent Events

    • 21 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Apr 2017.
    • 21 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Mar 2017.
    • 09 Nov 2016 According to a MEI Pharma media release, data from this study will be presented at at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top